Funding the NIH: Investing in medical research is vital to our health
Friday, February 03, 2012 (8 reads)
For millions of Americans and their families who suffer from serious illnesses and conditions, medical research is the beginning of hope. Our nation's investment in medical research funded by the National Institutes of Health over the past 60 years has led to many of the advances that are now helping Oregonians live longer and healthier lives.
Read More |   |
|
|
|
Galena Biopharma Announces Investigational New Drug Approval for Phase 2 Trial for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (trastuzumab)
Wednesday, January 04, 2012 (62 reads)
Randomized Phase 2 Clinical Study in 300 Patients for Adjuvant Breast Cancer to Initiate in 1H, 2012
LAKE OSWEGO, Ore., Jan. 5, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced that the U.S. Food and Drug Administration has approved the Investigational New Drug (IND) application for the Phase 2 combination trial with NeuVax™ (E75 plus GM-CSF) and Herceptin® (trastuzumab; Genentech/Roche). The trial is being funded by Galena Biopharma and Genentech/Roche through the Henry M. Jackson Foundation. Each company will provide their respective drugs for the 300 patient trial and approximately half of the funding necessary to complete the trial. The trial will be conducted at twenty sites worldwide and is expected to commence in the first half of 2012 under the direction of COL George E. Peoples, M.D., FACS, Director, Cancer Vaccine Development Program; Deputy Director, United States Military Cancer Institute; Professor (adjunct), Surgical Oncology, M.D. Anderson Cancer Center; Professor, Surgery, Uniformed Services University; Chief, Surgical Oncology, Brooke Army Medical Center.
Read More | |
|
Clear Catheter Systems Raises $4 Million in VC Funding
Tuesday, January 03, 2012 (62 reads)
BEND, Ore.--(BUSINESS WIRE)--Clear Catheter Systems, Inc., a leading developer of medical devices used in post surgical recovery announced that it has closed its first institutional round of financing. The $4 million round was co-led by Aphelion Capital and California Technology Ventures. Also participating in the financing was Research Corporation Technologies. Ned Scheetz, of Aphelion Capital and Alex Suh, of California Technology Ventures will join the board of directors. Clear Catheter Systems will utilize the capital from the latest round to respond to increasing demand for its lead product, the PleuraFlow® Active Tube Clearance® System, and drive commercialization in the United States and abroad.
Read More | |
|
Higher Education: Universities' Research Collaboration Boosts Oregon
Monday, December 19, 2011 (106 reads)
OregonLive.com
Published: Friday, December 16, 2011, 4:10 AM
By Guest Columnist Jonathan Fink
The competitive edge that has been largely overlooked in the recent uproar is the collaborative research environment built in Oregon over the past decade. Most clearly exemplified by three Signature Research Centers in nanotechnology, drug development and energy-efficient construction, the level of cooperation among the state's four research universities, high-tech industry, state government and federal laboratories has few parallels across the country.
Read More | |
|
 |
|
|